Improving the discovery of effective antibody therapies
Official title: Scaling function-first antibody discovery leveraging memory B cells
Funded at Partillion Bioscience Corporation · NIH-11185382 · Data updated 2026-11-12
This study is working on a faster and easier way to find important proteins called monoclonal antibodies, which help create better treatments for patients, so you can get more effective therapies more quickly and at a lower cost.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Partillion Bioscience Corporation NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,000,000 |
| NIH project number | 1R44AI193415-01 |
| Project ID | NIH-11185382 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who may benefit from monoclonal antibody therapies, particularly those with conditions that could be treated by new antibody treatments.
✕Less likely to help
Patients who do not require monoclonal antibody therapies or have conditions unrelated to antibody treatments may not benefit from this research.
What this research studies
This research focuses on enhancing the process of discovering monoclonal antibodies, which are crucial for many therapies. It aims to develop new workflows that utilize specialized hydrogel microparticles to sort B cells and antibody-secreting cells based on the antibodies they produce. By increasing the throughput of antibody screening by ten times, this research seeks to improve the efficiency and cost-effectiveness of antibody discovery, making it more accessible for various applications. Patients may benefit from more effective treatments as a result of improved antibody therapies.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and affordable antibody-based therapies for patients.
How similar studies have gone: Other research has shown success in improving antibody discovery methods, but this approach utilizing hydrogel microparticles is relatively novel.
Where this research is happening
-
Partillion Bioscience Corporation
Los Angeles, United States Active
Researchers
- Principal investigator: De Rutte, Joseph — Partillion Bioscience Corporation
- Study coordinator: De Rutte, Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.